My Plastic Surgeon USA Main Page
The Source for Finding Plastic Surgeons
My Plastic Surgeon USA Main Quickmenu
Explore
Search for a Board Certified Plastic Surgeon
find your doctor today!
perform a search:
by state
by last name
by practice name
Plastic Surgery Financing
read our financing FAQ and apply online!
Forum
join other women in our active online community!
Learn
Ask an Expert
have a question? ask a board certified plastic surgeon now!
Plastic Surgery Blog
keep up to date with the very latest advances and news on our plastic surgery blog!
Procedures
click below to learn
more about:
Botox®
Breast Augmentation
Breast Lift
Breast Reduction
Eyelid Surgery
Facelift
Liposuction
Nose Surgery
Procedures for Men
Tummy Tuck
Article Finder
peruse past and current articles by keyword.
FAQ
a list of frequently asked questions answered by our doctors.
Newsletter
stay on top of the latest news in plastic surgery.
See Results
Before and After
Photo Gallery
take a look at others' results:
Abdominoplasty
Body Lift
Brachioplasty
Liposuction
Thigh Lift
Breast Augmentation
Breast Lift
Breast Reduction
Breast Revision
Gynecomastia
Blepharoplasty
Browlift
Facelift
Rhinoplasty
Success Stories
women who have been there tell their stories!
 
 
Articles


New Head-to-Head Study Shows Longer Duration of Effect and Greater Patient Satisfaction With BOTOX® Cosmetic Compared to Dysport®
Study Finds Superior Efficacy with Comparable Tolerability at Recommended Doses

press release from Cranley Clinic

SAN FRANCISCO, March 3 -- A new study comparing the efficacy and tolerability of two different formulations of botulinum toxin type A has shown that, at recommended doses, effects of treatment with BOTOX® Cosmetic (botulinum toxin type A), also known as VISTABEL® / VISTABEX® in Europe, for moderate to severe glabellar lines (the vertical "frown lines" between the brows) last longer and patients are more satisfied with their appearance than patients treated with Dysport®, a brand of botulinum toxin type A that is available in Europe but not yet approved for use in the U.S. The study is being presented at the American Academy of Dermatology's Annual Winter Meeting in San Francisco.(i)

"There are important biological, pharmacological and clinical differences between botulinum toxin formulations and they are not interchangeable at a single dosing ratio," said Nicholas Lowe, M.D., FRCP, principal investigator for the study. "This study suggests that Dysport® may need to be used at higher doses than the currently recommended dose of 50 units for the treatment of glabellar lines to achieve duration of effect and patient satisfaction comparable to BOTOX® Cosmetic."

For this 16-week, randomized, double-blind study, 62 patients with moderate to severe glabellar lines were treated with either BOTOX® Cosmetic at the dose approved by the U.S. Food and Drug Administration (FDA) for the treatment of glabellar lines (20 units), or with Dysport® (50 units, reported in a recent study to be the optimal dose of this formulation(ii)). To evaluate treatment efficacy, investigators assessed standardized photographs of patients' glabellar lines taken at baseline and weeks 2, 8, 12, and 16 - one of the most objective means of assessing glabellar line severity. In addition, patients rated their feelings of attractiveness and feelings of satisfaction with their appearance on a 7-point scale.

In both treatment groups, the number of patients with at least a 1-grade improvement in the severity of their glabellar lines peaked at week 8. However, this improvement lasted longer in the BOTOX® Cosmetic-treated group than in the Dysport®-treated group, with 77% of BOTOX® Cosmetic patients vs. 59% of Dysport® patients maintaining improvement at week 12; and with 53% vs. 28% maintaining improvement at week 16. In addition, patients' mean scores for how attractive they felt and how satisfied they felt with their appearance were consistently higher in the BOTOX® Cosmetic treatment group than in the Dysport® group throughout the 16-week study period, with statistical significance achieved for both criteria at week 12. Both products were well-tolerated.

"Other studies have suggested that instead of the 2.5:1 Dysport® to BOTOX® Cosmetic ratio used in our study, a more appropriate dose comparison may be 4:1 or 5:1 Dysport® to BOTOX® Cosmetic," said Dr. Lowe. "Further dose escalation studies are needed to determine an optimum comparative dosage and whether higher doses can achieve comparable efficacy to BOTOX® Cosmetic without raising the incidence of unacceptable side effects."

This study was funded by an unrestricted grant from Allergan, Inc. to Clinical Research Specialists, Santa Monica, CA.

(i) Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Presented at the 64th annual meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA. Poster #232.

(ii) Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study in the efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004;51:223-233.


More Articles

All MyPlasticSurgeonUSA.com Doctors are Board-Certified Physicians
Be sure to tell friends and family about MyPlasticSurgeonUSA.com!
My Plastic Surgeon USA is sponsored and made possible by the
plastic surgeons featured on this website.

MyPlasticSurgeonUSA.com is solely a provider of information.
If the information provided is used by the Internet user, said use is at that person's sole risk and discretion.
Please read the full Privacy Policy & Terms and Conditions.

By Entering the My Plastic Surgeon USA Web Site, You are Agreeing to be bound by these Terms & Conditions.